Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Liver function testing in patients on HMG-CoA reductase inhibitors.

Andrade SE, Donahue JG, Chan KA, Watson DJ, Platt R.

Pharmacoepidemiol Drug Saf. 2003 Jun;12(4):307-13.

PMID:
12812011
2.
3.

Statins and liver toxicity: a meta-analysis.

de Denus S, Spinler SA, Miller K, Peterson AM.

Pharmacotherapy. 2004 May;24(5):584-91. Review.

PMID:
15162892
4.

Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.

Martin JE, Cavanaugh TM, Trumbull L, Bass M, Weber F Jr, Aranda-Michel J, Hanaway M, Rudich S.

Clin Transplant. 2008 Jan-Feb;22(1):113-9. doi: 10.1111/j.1399-0012.2007.00780.x.

PMID:
18217912
5.
6.
7.

Compliance to recommended liver function monitoring in patients on statin therapy.

Leaver H, Keng Lim T, Thomson P, Leaver J, Choy AM, Lang CC.

Cardiovasc Ther. 2009 Summer;27(2):96-100. doi: 10.1111/j.1755-5922.2009.00082.x.

PMID:
19426246
8.

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

Blais L, Desgagné A, LeLorier J.

Arch Intern Med. 2000 Aug 14-28;160(15):2363-8.

PMID:
10927735
10.

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.

Chang JT, Staffa JA, Parks M, Green L.

Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):417-26.

PMID:
15269925
11.
12.

[Toxic liver damage caused by HMG-CoA reductase inhibitor].

Heuer T, Gerards H, Pauw M, Gabbert HE, Reis HE.

Med Klin (Munich). 2000 Nov 15;95(11):642-4. German.

PMID:
11143546
13.

Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities.

Yazici Y, Erkan D, Harrison MJ, Nikolov NP, Paget SA.

Clin Exp Rheumatol. 2005 Jul-Aug;23(4):517-20.

PMID:
16095122
14.

HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.

Nakashima A, Nakashima R, Ito T, Masaki T, Yorioka N.

Diabet Med. 2004 Sep;21(9):1020-4.

PMID:
15317608
15.

Health outcomes following liver function testing in primary care: a retrospective cohort study.

McLernon DJ, Donnan PT, Ryder S, Roderick P, Sullivan FM, Rosenberg W, Dillon JF.

Fam Pract. 2009 Aug;26(4):251-9. doi: 10.1093/fampra/cmp025. Epub 2009 May 12.

16.

Statin safety: an assessment using an administrative claims database.

Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH.

Am J Cardiol. 2006 Apr 17;97(8A):61C-68C. Epub 2006 Jan 30.

PMID:
16581331
17.

Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.

Segarra-Newnham M, Parra D, Martin-Cooper EM.

Pharmacotherapy. 2007 Jun;27(6):845-51.

PMID:
17542767
18.

Outcomes of routine testing of liver enzymes in institutionalized geriatric patients.

Steinberg EN, Cho-Steinberg HM, Howden CW.

Am J Manag Care. 1997 Feb;3(2):267-70.

19.

Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature.

Rudski L, Rabinovitch MA, Danoff D.

Medicine (Baltimore). 1998 Nov;77(6):378-83. Review.

20.

Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.

Fraunfelder FW, Richards AB.

Ophthalmology. 2008 Dec;115(12):2282-5. doi: 10.1016/j.ophtha.2008.08.006. Epub 2008 Oct 18.

PMID:
18930555
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk